Add BrightSurf on Google Email

Characterizing antibodies targeting antisense oligonucleotide modifications

Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalNucleic Acid Therapeutics·TypeExperimental study·DateJul 31, 2025

Nearly 1 in 6 older adults take aspirin despite no history of heart disease

A study of over 2,500 adults aged 50-80 found that nearly 1 in 6 take aspirin for cardiovascular protection without a history of heart disease. Despite revised guidelines reducing aspirin use for primary prevention after age 70, many patients are unaware of the increased risk of bleeding.

SourceMichigan Medicine - University of Michigan·JournalJournal of the American College of Cardiology·TypeData/statistical analysis·DateJul 2, 2025

Too many medicines, too many hospital visits: New study highlights hidden risk for older adults

A new study from the University of Bath found that inappropriate polypharmacy is a major driver of emergency hospital admissions among adults aged 65 and over. The researchers developed a digital tool to proactively identify older adults at risk of medication-related harm, which could reduce preventable emergency hospitalisations.

SourceUniversity of Bath·JournalAge and Ageing·TypeData/statistical analysis·DateJul 1, 2025

Unlocking precise composition analysis of nanomedicines

Researchers developed a technique to separate and quantify ions, nanoparticles, and aggregates in nanomedicines, improving quality control for advanced pharmaceutical products. This method ensures the safe use of metal-based nanomedicines by distinguishing between their different forms.

SourceChiba University·JournalTalanta·TypeExperimental study·DateMay 29, 2025

Headway in Alzheimer’s disease care: new guidance provides recommendations for use of anti-amyloid monoclonal antibodies

The Swiss Memory Clinics network has released new national guidelines on the use of anti-amyloid monoclonal antibodies, such as Lecanemab and Donanemab, for treating Alzheimer's disease. The guidelines outline criteria for patient selection, biomarker confirmation, and infrastructure requirements to support safe treatment delivery.

SourceKarger Publishers·JournalNeurodegenerative Diseases·DateApr 24, 2025

Study finds women much more likely to be aware of and have good understanding of obesity drugs

A study published by the European Association for the Study of Obesity found that women are significantly more aware of and have a better understanding of obesity drugs like semaglutide and tirzepatide. Understanding tolerable side effects, effectiveness, and ability to maintain weight loss is crucial for people commencing treatment.

New study reveals potential link between GLP1 agonists and depression: Calls for urgent attention

A recent study published in Current Neuropharmacology suggests a potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists and depression, particularly in individuals with low dopamine function. The authors urge caution and recommend genetic testing to identify individuals at risk before prescribing these medications.

SourceBentham Science Publishers·JournalCurrent Neuropharmacology·DateApr 17, 2025

Researchers identify safer pathway for pain relief

A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...

SourceUniversity of Florida·JournalNature Communications·TypeExperimental study·DateApr 8, 2025

Fees can help the FDA ensure food safety

A new analysis suggests that fees for food companies could generate much-needed resources for the FDA to strengthen its oversight of foods and keep unsafe ingredients out of the market. The FDA's current lack of resources hampers its ability to ensure the safety of the country's food supply, with growing concerns about the agency's ina...

SourceNew York University·JournalHealth Affairs·DateApr 7, 2025

Local access to abortion services expanded with mifepristone in community pharmacies

The expansion of mifepristone to community pharmacies has increased access to abortion services in Ontario, with the proportion of regions with a pharmacy or procedural provider growing from 20% to 82%. The study found that access to abortion services improved in both urban and rural areas.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeData/statistical analysis·DateApr 7, 2025

Obesity Action Coalition & The Obesity Society send letter to FDA on behalf of more than 20 leading organizations & providers urging enforcement of compounding regulations

More than 20 leading organizations and providers urge the FDA to take action following the recent resolution of GLP-1 medicine shortages. Signatories include the Alliance for Women’s Health & Prevention, Association of Black Cardiologists, and National Hispanic Medical Association.

Stem cell transplant clears clinical safety hurdle for the treatment of wet age-related macular degeneration

A new stem cell transplant treatment has shown promising results in clearing clinical safety hurdles for the treatment of wet age-related macular degeneration. The treatment involves removing abnormal blood vessels and transplanting stem cell-derived retinal cells to replace damaged or lost retinal cells.

SourceInternational Society for Stem Cell Research·JournalStem Cell Reports·DateFeb 27, 2025

Older patients can inadvertently be put at risk when they are taken off blood-thinning drugs

A study by University of Bath researchers found that stopping anticoagulants for patients aged 75 and over does not significantly affect the risk of major bleeding, but increases the risk of serious events like stroke and death. This highlights the need for clinicians to carefully consider the risks of stopping anticoagulation therapy ...

SourceUniversity of Bath·JournalHeart·TypeObservational study·DateFeb 17, 2025

Gene therapy may be “one shot stop” for rare bone disease

A new study adds weight to the safety and effectiveness of a gene therapy for hypophosphatasia, a rare inherited disorder that causes abnormal bone development. The treatment, AAV8-TNAP-D10, has shown promising results in mice models, with female mice achieving improvements in bone and teeth at lower doses.

SourceSanford Burnham Prebys·JournalJournal of Bone and Mineral Research·TypeExperimental study·DateFeb 3, 2025

NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.

SourceNational University of Singapore·JournalAdvanced Functional Materials·TypeExperimental study·DateJan 27, 2025